Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, March 9, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that solifenacin succinate (generic name, “solifenacin”) oral suspension...
Tottori and Tokyo, March 6, 2018 - Tottori University (President: Ryota Teshima, “Tottori University”) and Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka,...
Tokyo, March 1, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that 40 mg XTANDI Tablets and 80 mg XTANDI Tablets received...
Tokyo, February 16, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) launched “CNN Tomorrow’s Hero” as a part of its global corporate brand campaign which...
Tokyo, February 13, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...
Tokyo, February 8, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the results of two Phase 3 trials (RAJ3 and RAJ4 trials) on Peficitinib...
Astellas Announces Personnel Changes and Organizational Changes
Pfizer Contacts: For Media Sally Beatty 212-733-6566 sally.beatty@pfizer.com For Investors Ryan Crowe 212-733-8160 ryan.crowe@pfizer.com Astellas Contacts: For Media Tarsis Lopez 847-224-8374...
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that, at a meeting of the Board of Directors held today, it...
(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and...
Tokyo, January 31, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “the Company” ) today announced that its Board of Directors approved a change in its...
TOKYO – January 26, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data to be presented at the 2018 Genitourinary Cancers...
Tokyo, Janurary 24, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Mitobridge, Inc....
TOKYO – January 23, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the European Commission (EC) has issued Orphan...
TOKYO and SAN DIEGO – Jan. 22, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL) announced today that...
Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters, Tokyo; President and CEO:...
Tokyo and City, January 11, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) and Kotobuki Pharmaceutical Co., Ltd. (President and CEO; Hiroshi...
TOKYO (January 9, 2018) - Amgen Astellas BioPharma K.K. (Headquarters Tokyo; President and Representative Director Steve Sugino “Amgen Astellas BioPharma”) and Astellas Pharma Inc....
Tokyo, December 20, 2017 - Astellas Pharma Inc. today announced that the company's President and CEO Yoshihiko Hatanaka will present at the 36 th Annual J.P. Morgan Healthcare Conference on...
TOKYO – December 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the first reported data of the investigational agent...
Tokyo, December 6, 2017 - Astellas Pharma Inc. (Tokyo, President and CEO: Yoshihiko Hatanaka, “Astellas” ), the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori...
Tokyo and Cambridge, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Mitobridge, Inc.1 (President and CEO: Kazumi Shiosaki,...
Tokyo, November 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that that it submitted an application for marketing approval in...
TOKYO – November 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data in acute myeloid leukemia (AML) research, including...
Tokyo, November 28, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that they have...
Tokyo and San Francisco, October 31, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Thomas B. Neff,...
Tokyo, October 30, 2017 – Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (President and...
Tokyo, October 30, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a screening collaboration agreement with Medicines...
Tokyo, October 19, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Universal Cells, Inc. (CEO: Claudia Mitchell, “Universal Cells”) today...
Tokyo, October 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has entered into a new collaborative research agreement with TB...
Tokyo and Osaka, October 11, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; Headquarters: Tokyo; TSE: 4503; “Astellas” ), Mitsubishi Tanabe Pharma Corporation (President...
TOKYO and BOTHELL, Wash., October 10, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Seattle Genetics Inc., Inc., (NASDAQ: SGEN) today announced...
TOKYO – October 11, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has granted...
Astellas Pharm Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and TOA EIYO LTD. (President: Atsuo Takahashi, “TOA EIYO”) announced that the companies have entered into...
Pfizer Contacts: For Media Sally Beatty (212) 733-6566 sally.beatty@pfizer.com For Investors Chuck Triano (212) 733-3901 charles.e.triano@pfizer.com Astellas Contact: For Media Tyler Marciniak...
Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for...
Tokyo, September 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for...
TOKYO (August 30, 2017) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...
TOKYO – August 22, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the first patient was dosed in the registrational Phase 3...
(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) Tokyo, August 1, 2017- Astellas Pharma Inc. (TSE: 4503, President and CEO:...
Tokyo (Japan), August 1, 2017 –LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka, Representative Director, President: Jiro Mizukawa, “LTL Pharma”) and Astellas Pharma Inc....
Tokyo, July 31, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has submitted an application for marketing approval of...
Follow us
